专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2807187A1 PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE 有权转让
标题翻译： PEPTIDANTAGONISTEN AUS DER CALCITONIN-CGRP-FAMILIE VON PEPTIDHORMONEN UND DEREN VERWENDUNG
公开(公告)号：EP2807187A1
公开(公告)日：2014-12-03
申请号：EP13703494.8
申请日：2013-01-25
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： C07K14/585 , A61K38/22
CPC分类号： C07K14/57527 , A61K38/00 , A61K38/225 , A61K38/23 , C07K14/585
摘要： The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an oc-helix; and a C-terminal fragment of modified calcitonin gene -related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide. The embodiments further provide treatment methods, including methods of treating a migraine, the methods generally involving administering to an individual in need thereof an effective amount of a subject peptide or composition.
摘要翻译：实施方案提供了修饰的降钙素基因相关肽拮抗剂，其包括修饰的降钙素基因相关肽或相关蛋白家族成员的N-末端片段，其中N-末端片段的至少两个残基是半胱氨酸（Cys）和至少一个氨基酸包括苏氨酸（Thr）残基的非苏氨酸取代; 中心芯，其中心芯包含α-螺旋; 和包含C-末端酰胺的修饰的降钙素基因相关肽或相关蛋白家族成员的C末端片段，其中C末端片段的至少一个氨基酸是苯丙氨酸（Phe），脯氨酸（Pro），酪氨酸（Pro Tyr）或羟脯氨酸（Hyp）或其药学上可接受的盐，以及包含受试肽的组合物，包括药物组合物。实施方案进一步提供治疗方法，包括治疗偏头痛的方法，所述方法通常涉及向有需要的个体施用有效量的受试肽或组合物。

2. 发明授权

EP2807187B1 PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE 有权转让
标题翻译：降钙素肽CGRP肽类激素家族的肽拮抗剂及其应用
公开(公告)号：EP2807187B1
公开(公告)日：2017-07-26
申请号：EP13703494.8
申请日：2013-01-25
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： C07K14/585 , C07K14/575 , A61K38/22 , A61K38/00
CPC分类号： C07K14/57527 , A61K38/00 , A61K38/225 , A61K38/23 , C07K14/585

3. 发明公开

EP3027644A1 CGRP AGONIST PEPTIDES 有权
标题翻译：降钙素基因相关肽AGONISTEN肽
公开(公告)号：EP3027644A1
公开(公告)日：2016-06-08
申请号：EP14752510.9
申请日：2014-07-29
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： C07K14/585 , A61K38/23 , A61P3/00 , A61P3/04 , A61P3/10
CPC分类号： C07K14/57527 , A61K38/00
摘要： The embodiments provide a calcitonin gene-related peptide (CGRP) agonist peptide or pharmaceutically acceptable salt thereof, including pharmaceutical compositions comprising a CGRP agonist peptide. The embodiments further provide treatment methods, including method of treating metabolic disorders and metabolic disorders selected from metabolic syndrome, diabetes and obesity. The methods involve administering to a subject in need thereof an effective amount of CGRP peptide.
摘要翻译：实施方案提供降钙素基因相关肽（CGRP）激动剂肽或其药学上可接受的盐，包括含有CGRP激动剂肽的药物组合物。实施方案还提供治疗方法，包括治疗代谢紊乱和代谢综合征，糖尿病和肥胖症的代谢紊乱的方法。所述方法包括向有需要的受试者施用有效量的CGRP肽。

4. 发明公开

EP4316595A3 USE OF CGRP RECEPTOR ANTAGONISTS IN TREATING GLAUCOMA 审中-实审
公开(公告)号：EP4316595A3
公开(公告)日：2024-04-17
申请号：EP23195196.3
申请日：2017-08-30
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： A61K38/17 , A61P3/06
CPC分类号： A61K38/1709 , A61P21/00 , A61P25/00 , A61P25/02 , A61P25/04 , A61P25/14 , A61P25/16 , A61P25/28 , A61P27/06 , A61P29/00 , A61P3/06 , A61P39/02 , A61P43/00 , A61P9/10 , Y02A50/30
摘要： Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.

5. 发明公开

EP4316595A2 USE OF CGRP RECEPTOR ANTAGONISTS IN TREATING GLAUCOMA 审中-实审
公开(公告)号：EP4316595A2
公开(公告)日：2024-02-07
申请号：EP23195196.3
申请日：2017-08-30
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： A61P27/06
摘要： Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.

6. 发明授权

EP3027644B1 CGRP AGONIST PEPTIDES 有权
公开(公告)号：EP3027644B1
公开(公告)日：2019-08-21
申请号：EP14752510.9
申请日：2014-07-29
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： C07K14/585 , C07K14/575 , A61K38/23 , A61P3/00 , A61P3/04 , A61P3/10

7. 发明公开

EP3506925A1 USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS 有权转让
公开(公告)号：EP3506925A1
公开(公告)日：2019-07-10
申请号：EP17769144.1
申请日：2017-08-30
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： A61K38/17 , A61P25/00 , A61P27/06

8. 发明公开

EP3272769A1 PEPTIDE ANTAGONISTS OF THE CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE 有权转让
公开(公告)号：EP3272769A1
公开(公告)日：2018-01-24
申请号：EP17175988.9
申请日：2013-01-25
申请人： Soares, Christopher, J.
发明人： Soares, Christopher, J.
IPC分类号： C07K14/585 , C07K14/575 , A61K38/22 , A61K38/23 , A61K38/00
CPC分类号： C07K14/57527 , A61K38/00 , A61K38/225 , A61K38/23 , C07K14/585
摘要： The embodiments provide a modified calcitonin gene-related peptide antagonist including an N-terminal fragment of modified calcitonin gene-related peptide or related protein family member where at least two residues of the N-terminal fragment are cysteine (Cys) and at least one amino acid comprises a non-threonine substitution of a threonine (Thr) residue; a central core where the central core comprises an α-helix; and a C-terminal fragment of modified calcitonin gene-related peptide or related protein family member comprising a C-terminal amide and where at least one amino acid of the C-terminal fragment is phenylalanine (Phe), proline (Pro), tyrosine (Tyr) or hydroxyproline (Hyp) or pharmaceutically acceptable salt thereof, as well as compositions, including pharmaceutical compositions, comprising a subject peptide. The embodiments further provide treatment methods, including methods of treating a migraine, the methods generally involving administering to an individual in need thereof an effective amount of a subject peptide or composition.

9. 发明专利

CA3035561A1 USE OF CGRP RECEPTOR ANTAGONISTS IN NEUROPROTECTION AND NEUROLOGICAL DISORDERS 未知
公开(公告)号：CA3035561A1
公开(公告)日：2018-03-08
申请号：CA3035561
申请日：2017-08-30
申请人： SOARES CHRISTOPHER J
发明人： SOARES CHRISTOPHER J
IPC分类号： A61K38/17 , A61P25/00 , A61P27/06
摘要： Provided herein are treatment methods, including methods of treating nerve damage, methods of neuroprotection, methods of treating glaucoma and methods of lowering LDL levels. The methods generally involve administering to an individual in need thereof an effective amount of a CGRP receptor antagonist peptide or composition.

10. 发明专利

ES2819825T3 Antagonistas peptídicos de la familia calcitonina CGRP de hormonas peptídicas y su uso 未知
公开(公告)号：ES2819825T3
公开(公告)日：2021-04-19
申请号：ES17175988
申请日：2013-01-25
申请人： SOARES CHRISTOPHER J
发明人： SOARES CHRISTOPHER
IPC分类号： C07K14/585 , A61K38/00 , A61K38/22 , A61K38/23 , C07K14/575
摘要： Un antagonista del péptido relacionado con el gen de la calcitonina, o una sal farmacéuticamente aceptable del mismo, teniendo dicho antagonista la estructura de Fórmula I: X1-Y1-Z1 (I) en donde: X1 es X11-X12-X13-X14-X15-X16-X17 (SEQ ID NO: 16), en donde X11 se selecciona del grupo que consiste en Ala, Cys y Gly, y X12 se selecciona del grupo que consiste en Cys y Ser, siempre que uno de X11 y X12 sea Cys, X13 se selecciona del grupo que consiste en Arg, Asn, Asp y Val, X14 se selecciona del grupo que consiste en Leu, Phe y Thr, X15 se selecciona del grupo que consiste en Ala, Gly y Ser, X16 se selecciona del grupo que consiste en Ala, Ile, Leu, Ser y Val, y X17 es Cys; y Y1 se selecciona del grupo que consiste en -Val-Leu-Gly-Arg-Leu-Ser-Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro- Arg-Thr-Asn-(SEQ ID NO: 34), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn- (SEQ ID NO: 35), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asp-(SEQ ID NO: 37), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asn-(SEQ ID NO: 38), -Val- Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-(SEQ ID NO: 39), -Val-Leu-Gly-Lys- Leu-Ser-Gln-Glu-Leu-His-Lys-Met-Gln-Thr-Tyr-Pro-Arg-Thr-Asp (SEQ ID NO: 40), -Leu-Leu-Gly-Lys-Leu-Ser-Gln- Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Thr-Arg-Thr-Asp-(SEQ ID NO: 41), -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His- Lys-Leu-Gln-Thr-Phe-Pro-Arg-Thr-Asp-(SEQ ID NO: 42), -Met-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Leu-His-Lys-Leu- Gln-Thr-Phe-Pro-Arg-Thr-Asp-(SEQ ID NO: 43) y -Val-Leu-Gly-Lys-Leu-Ser-Gln-Asp-Ile-His-Lys-Leu-Gln-Thr-His- Pro-Arg-Thr-Asp-(SEQ ID NO: 44); y Z1 es Val-Gly-Ser-Lys-Ala-Phe-NH2.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式